GlassScriptPhysician profile
Fakhar Ijaz
NPI 1487653820
$1,565.62
in general payments reported to CMS, 2019-2025
17 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $199 · 2021: $208 · 2022: $290 · 2023: $159 · 2024: $315 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556 · Education: $57.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.95 |
| Education | $57.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $251.83 | 2019-2024 | Lokelma |
| Glaxosmithkline, LLC. | $212.17 | 2020-2025 | Benlysta, Shingrix |
| Fresenius USA Marketing, INC. | $175.60 | 2019-2024 | Velphoro |
| Amgen INC. | $160.71 | 2021-2024 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $143.81 | 2020-2022 | |
| Ardelyx, INC. | $116.77 | 2024-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $113.90 | 2019-2023 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $82.29 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $62.21 | 2019 | |
| Calliditas Therapeutics US INC. | $57.63 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $43.58 | 2023-2024 | |
| Opko Pharmaceuticals, LLC | $39.67 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $35.82 | 2023-2025 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $20.66 | 2024 | Crysvita |
| Vifor Pharma, INC. | $17.80 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $15.75 | 2019 | |
| Akebia Therapeutics INC | $15.42 | 2025 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fakhar Ijaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.